Neon Therapeutics

Neon Therapeutics is a clinical-stage biopharmaceutical company. It is focused in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. The company's pipeline products are NEO-PV-01, NEO-PTC-01, and NEO-SV-01.

Phase 1 Clinical Trial of Personal Neoantigen-Targeted T Cell Therapy Expected to Initiate in Third Quarter 2020 Phase 1 Clinical Trial of Personal Neoantigen-Targeted T Cell Therapy Expected to Initiate in Third Quarter 2020

Neon Therapeutics Announces Acceptance of European Clinical Trial Authorization Application for NEO-PTC-01

BioNTech SE

BioNTech's Acquisition Of Neon Highlights Potential Use Of Neoantigens For Cancer Treatment

Adaptimmune Therapeutics

Aquestive Therapeutics Inc

Dare Bioscience

Nektar Therapeutics

As the biotechnology group is pushing near all-time highs, this past week played host to a huge number of biotech movers.

This Week’s Biggest Biotech Movers

Neon Therapeutics (NTGN ) news for Thursday about a $67.00 million deal with BioNTech (BNTX) has NTGN stock soaring on Thursday.
The post Neon Therapeutics News: NTGN Stock Rockets 38% on BioNTech Deal appeared first on InvestorPlace.

Neon Therapeutics News: NTGN Stock Rockets 38% on BioNTech Deal

Neon Therapeutics Inc. (NASDAQ: NTGN) shares shot up on Thursday after the firm announced that it will be acquired by BioNTech SE (NASDAQ: BNTX).

Are Neon Therapeutics’ Shareholders Getting Enough in the Buyout?

MAINZ, Germany and CAMBRIDGE, Mass., Jan.  16, 2020  (GLOBE NEWSWIRE) -- BioNTech (Nasdaq: BNTX, “BioNTech”) and Neon Therapeutics, Inc. (Nasdaq: NTGN, “Neon”) today announced that they have entered into a definitive merger agreement under which BioNTech will acquire Neon in an all-stock transaction valued at approximately $67.0 million. Neon is a biotechnology company developing novel neoantigen-based T cell therapies. Upon closing, it will operate as a subsidiary of BioNTech, a global clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The transaction will combine two organizations with a common culture of pioneering translational science and a shared vision for the future of cancer immunotherapy.

BioNTech to acquire Neon to strengthen global leadership position in T cell therapies

Study of NEO-PTC-01 in metastatic melanoma patients expected to initiate in first half of 2020 Study of NEO-PTC-01 in metastatic melanoma patients expected to initiate in first half of 2020

Neon Therapeutics Submits European Clinical Trial Authorization Application for Personal Neoantigen-Targeted T Cell Therapy NEO-PTC-01

Shares of Neon Therapeutics NTGN, -4.03% were up 19% in after-hours trading Wednesday after the company announced a corporate restructuring that includes cutting 24% of its workforce.

Shares of Neon Therapeutics rise on restructuring plans

Lead program, NEO-PTC-01, is a personalized neoantigen adoptive T cell therapy candidate to address refractory solid tumors

Neon Therapeutics Announces New Strategic Focus on Novel T Cell Programs

Updated Results from NT-001 Trial of NEO-PV-01 Demonstrate Prolonged Progression-Free and Overall Survival vs. Historical Benchmark Data

Neon Therapeutics Announces Updated Data Presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Proprietary class II prediction tool achieved up to a 61-fold improvement in predicting MHC class II peptides compared to standard methods

Neon Therapeutics Announces Publication in Immunity of Novel Approach to Predict MHC Class II Cancer-Specific Neoantigens

Neon Therapeutics achieved positive results using NEO-PV-01 when combined with OPDIVO in patients with a few types of cancer.

Neon's Data In Cancer Study Points To Personalized Treatment Advancement In Immunotherapy Space

Neon Therapeutics (NASDAQ: NTGN) shares are trading higher after the company announced its personal neoantigen vaccine study demonstrated prolonged progression-free survival in advanced or metastatic melanoma, non-small cell lung and bladder cancers.

News for Neon Therapeutics Stock (NTGN)